6533b861fe1ef96bd12c57b9

RESEARCH PRODUCT

The presence of genomic imbalances is associated with poor outcome in patients with burkitt lymphoma treated with dose-intensive chemotherapy including rituximab.

C. OlivierRocío BenitoEva LumbrerasJuan Luis GarcíaJosep-maria RiberaCarlos GrandeLuis A. Corchete-sánchezAlfonso García De CocaJesus M Hernández-sánchezMaribel Forero-castroMaribel Forero-castroJordi RiberaPere BarbaEstrella CarrilloMaría Hernández-sánchezLourdes EscodaCristina RobledoJavier MenárguezJesús M. Hernández-rivasMar Tormo

subject

OncologyMalemedicine.medical_treatmentarray-based comparative genomic hybridization (aCGH)Intensive chemotherapyKaplan-Meier EstimateBioinformatics0302 clinical medicinerituximabAntineoplastic Combined Chemotherapy ProtocolsYoung adultComparative Genomic HybridizationGenomeArray-based comparative genomic hybridizationBurkitt lymphomaHigh-Throughput Nucleotide SequencingHematologyMiddle AgedPrognosisBurkitt Lymphomahumanities3. Good healthTreatment Outcome030220 oncology & carcinogenesisoutcomeRituximabFemaleRituximabmedicine.drugAdultmedicine.medical_specialtyAdolescenteducationBiologyNext-generation sequencing outcome03 medical and health sciencesYoung AdultInternal medicinemedicineHumansIn patientAgedChromosome AberrationsChemotherapymedicine.diseaseGNA13Lymphomastomatognathic diseasesnext-generation sequencing030215 immunologyComparative genomic hybridization

description

Part of this study has been reported as an oral presentation at the EHA Meeting in Vienna 2015.

10.1111/bjh.13849https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/bjh.13849